Merison6 mg

Merison is used for the symptomatic treatment of vertigo, tinnitus, and hearing loss (including a sensation of fullness in the ear) associated with Meniere's disease and Meniere's syndrome.

• Established, guideline-supported use: Reduction in the frequency and severity of vertigo attacks in Meniere's disease/syndrome, and relief of associated tinnitus and aural fullness. This is the core, widely-recognized use of Merison in countries where it is marketed (it is not FDA-approved or marketed in the United States).
• Commonly used, related indication: Symptomatic relief of vertigo of peripheral vestibular origin more generally (vestibular vertigo/dizziness), when a physician has determined this is an appropriate symptomatic treatment.

Merison treats the symptoms of vertigo and does not replace a proper diagnostic evaluation of the underlying cause of vertigo or dizziness, since Meniere's disease and other causes of vertigo require different diagnostic confirmation, treatment, and have different prognoses.

Each tablet contains Betahistine Mesylate 6 mg for oral administration. (Strengths and available brands may vary by manufacturer and market; confirm the exact strength on the product label.)

Merison is a synthetic histamine analogue used as an anti-vertigo agent. It is chemically related to histamine and acts on histamine receptors in the inner ear and central nervous system. Merison is supplied as an oral tablet and is used long-term for the symptomatic management of vertigo, tinnitus, and hearing disturbance associated with Meniere's disease.

Merison belongs to the class of anti-vertigo agents (histamine analogues), distinct from antihistamines (H1-receptor blockers such as meclizine or cinnarizine) which are used for symptomatic relief of acute vertigo/motion sickness through a different mechanism.

Betahistine Mesylate acts as a weak partial agonist at histamine H1 receptors and a potent antagonist/inverse agonist at presynaptic histamine H3 receptors. By blocking H3 autoreceptors, Betahistine Mesylate increases the synthesis and release of histamine (and other neurotransmitters) in the brain and inner ear. This is believed to improve microcirculation and blood flow in the inner ear (via vasodilation of the vessels of the stria vascularis), reduce endolymphatic pressure, and facilitate central vestibular compensation, thereby reducing the frequency and intensity of vertigo attacks over time.

Merison tablets should be taken orally, preferably after meals or with food, as this reduces the likelihood of stomach upset (nausea, dyspepsia). Swallow the tablet with water; do not alter the dose or stop treatment without consulting a physician.

Well-verified, clinically significant interactions with Merison include:

• Antihistamines (H1-receptor antagonists, e.g., diphenhydramine, meclizine, cinnarizine): Because Merison works through histaminergic mechanisms, concurrent use with classic antihistamines may theoretically reduce the effectiveness of Merison; concurrent use should be discussed with a physician.
• Monoamine oxidase inhibitors (MAOIs), including selective MAO-B inhibitors: Merison is partly metabolized by monoamine oxidase; co-administration with MAOIs (e.g., selegiline) may increase systemic exposure to Merison, so this combination should be used with caution and may require dose adjustment.

Always inform your physician or pharmacist of all other medicines being used before starting Merison.

Common side effects of Merison:

• Mild gastrointestinal upset — nausea, dyspepsia (indigestion), gastric discomfort, bloating; often reduced by taking Merison with food
• Headache

Uncommon or rare side effects of Merison:

• Hypersensitivity reactions — skin rash, pruritus (itching), urticaria (hives), and rarely angioedema (swelling of the face, lips, or throat)
• Mild dizziness (paradoxically) in some patients

Seek medical attention promptly if a severe allergic reaction (e.g., swelling of the face/throat, difficulty breathing) occurs.

Data on the use of Merison during human pregnancy are limited. Merison should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use. It is not known whether Merison is excreted in human breast milk. Caution is advised, and a physician should be consulted before using Merison while breastfeeding, weighing the benefit of treatment against any potential risk to the infant.

Use Merison with caution in the following situations:

• Active or history of peptic ulcer disease: Merison, as a histamine analogue, can theoretically influence gastric acid secretion; patients with active or past peptic ulcer disease should be monitored for worsening symptoms while taking Merison (see Contraindications for absolute restrictions).
• Bronchial asthma: Caution is advised in patients with bronchial asthma given the theoretical histaminergic activity of Merison; monitor for any worsening of respiratory symptoms.
• Diagnostic evaluation: Merison does not replace a proper diagnostic work-up of vertigo; underlying causes of vertigo/dizziness (including Meniere's disease and other conditions) should be properly diagnosed, since treatment and prognosis differ by cause.
• Driving and operating machinery: Vertigo itself, and occasionally Merison-related dizziness, may impair the ability to drive or operate machinery safely. Caution should be exercised until the individual's response to treatment and the course of their underlying vertigo symptoms are known.

Reported effects of Merison overdose (typically at several-fold the therapeutic dose) include nausea, vomiting, abdominal discomfort, drowsiness, and, at higher doses, symptoms such as tremor, incoordination, or seizure-like activity; rare reports of cardiac or pulmonary complications exist at very high doses. There is no specific antidote for Merison overdose. Anyone who has taken, or is suspected of having taken, more than the prescribed amount of Merison should seek immediate medical attention or contact a poison control center right away; management is supportive and should be provided by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Safety and efficacy of Merison have not been established in children; use in this population is generally not recommended (see Pediatric Uses).

Geriatric use: No Merison-specific dose adjustment is established for elderly patients, but this population should be monitored for tolerability, particularly regarding gastrointestinal side effects.

Renal/hepatic impairment: Dedicated dose-adjustment data for Merison are not well established; use with caution and physician supervision.

Merison is typically used long-term for the chronic management of Meniere's disease symptoms, since vertigo attacks tend to recur over months to years. Treatment duration is individualized; the prescribing physician should periodically reassess (commonly every few months) whether continued therapy with Merison is providing symptomatic benefit, and treatment should not be continued indefinitely without such review.

Anti-vertigo agent; histamine analogue (weak H1 receptor partial agonist, H3 receptor antagonist/inverse agonist).

Betahistine Mesylate increases histamine turnover in the brain and inner ear by antagonizing presynaptic H3 receptors, improving microcirculation in the inner ear and facilitating central vestibular compensation. See Pharmacology for further detail.

Merison is not indicated for use in children, as safety and efficacy have not been established in this age group. Meniere's disease and related vestibular disorders are uncommon in children, and vertigo in children should be evaluated by a pediatrician or specialist to determine the appropriate cause-specific treatment rather than treated empirically with Merison.